AbCellera (ABCL) on 7/12 with an unusual large opening sale of 3364 January $14 ITM puts for $4.30, strongly bullish play in the small med-tech. ABCL shares are clearing a flag and its 200-MA today with impressive strength, shares now nearly doubling since May. ABCL has a full-stack, artificial intelligence-, or AI, powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. Its technology increases the speed and the probability of success of therapeutic antibody discovery, including enabling discovery against targets that may otherwise be intractable. ABCL has a market cap of $3.2B and trades 14.5X EBITDA and 5.9X EV/Sales with revenues seen rising 27% this year and also trades 5.9X cash with no debt. Piper with a $21 target positive eon the royalty revenue from Lilly-partnered Covid antibody sales. Benchmark started at Buy in December with a $27 target citing multiple shots on goal and lots of potential partnership programs.